Condition: Lung Adenocarcinoma Stage III · Lung Adenocarcinoma Stage IV · EGFR Gene Mutation · Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
To explore the efficacy and safety of neoadjuvant furmonertinib combined with bevacizumab in the treatment of resectable and potentially resectable stage III-IVA EGFR mutation-positive lung adenocarcinoma.
This description comes directly from the study's public registry record.
Peng Zhang, MD,PhD · +8613512185932 · zhangpeng1121@outlook.com
Always discuss trial participation with your own doctor first.
| Shanghai Pulmonary Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05503667